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One Sentence Summary: The first-in-man trial of tolerization with antigen-coupled cells for 
treatment of MS demonstrates the feasibility, safety and tolerability of this novel therapeutic 
approach and shows first evidence for an antigen-specific tolerization upon dosing with 1x109 or 
higher numbers of antigen-coupled cells. 
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Abstract: The aim of this first-in-man trial was to assess the feasibility, safety and tolerability of 
a novel tolerization regimen in MS patients, that employs a single infusion of autologous 
peripheral blood mononuclear cells chemically coupled with seven myelin peptides (MOG1-20, 
MOG35-55, MBP13-32, MBP83-99, MBP111-129, MBP146-170 and PLP139-154). An open-
label, single center, dose escalation study was performed in 7 relapsing-remitting and 2 
secondary progressive MS patients, who were off-treatment for standard therapies. All patients 
had to show T cell reactivity against at least one of the myelin peptides used in the trial. 
Neurological, MRI, laboratory and immunological examinations were performed to assess the 
safety, tolerability and in vivo mechanisms of action of this regimen. We followed the overall 
patient immune response as well as responses to myelin antigens prior to and after administration 
of peptide-coupled PBMC. Overall, administration of antigen-coupled cells was feasible, had a 
favorable safety profile and was well tolerated in MS patients. Compared to the pre-treatment 
observation period there was no increase in clinical and MRI parameters of disease activity by 
this regimen. Patients receiving the higher doses (>1x109) of peptide-coupled cells had a 
decrease in antigen-specific T cell responses following peptide-coupled cell therapy. In summary, 
this first-in-man clinical trial of autologous peptide-coupled cells in MS patients, establishes the 
feasibility, and indicates good tolerability and safety of this novel therapeutic approach. 
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Introduction 
Approaches to induce antigen-specific tolerance in multiple sclerosis (MS) hold the promise to 
stop the pathogenic autoimmune response, thus preventing disease activity while at the same 
time avoiding the potentially severe side effects, which are associated with many of the currently 
employed immunotherapies (1, 2). In MS the primary target antigen/s is/are not known for 
certain, but it is well accepted that proteins within the myelin sheath, such as myelin basic 
protein (MBP), myelin oligodendrocyte protein (MOG) and proteolipid protein (PLP) are 
important targets of the autoreactive immune response (3). However, the target epitopes of 
myelin proteins differ between MS patients, and it is likely that the myelin-specific T cell 
reactivity may change over time (4-6). In relapsing-remitting animal models of MS, chronic 
demyelination leads to the generation of new T cell responses against multiple endogenous 
antigens, a process called epitope spreading, and these newly generated T cells are able to induce 
relapses, which can be inhibited by tolerance to the spread epitope (7, 8). Therefore, it is 
reasonable to assume, that the efficacy of antigen-specific therapies will not only depend on 
knowledge of the specific target antigens, but also on the ability to block epitope spreading at an 
early stage and thereby stop diversification of T cell autoreactivity. Consequently, antigen-
specific therapies should simultaneously target previously activated autoreactive T cells and also 
naïve autoreactive T cells specific for multiple myelin epitopes.  
Antigen-coupled cell tolerance is a tolerization strategy with a long-standing and excellent track 
with regard to efficacy and safety in several experimental models of autoimmune diseases, 
transplantation tolerance and allergic disease (9, 10). Antigen-specific tolerance is induced 
through carrier cells, which are pulsed with antigens in the presence of the chemical cross linker 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) (9, 11-15). Studies in experimental 
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autoimmune encephalomyelitis (EAE), an animal model of MS, have proven that a single i.v. 
injection of syngeneic splenocytes coupled with encephalitogenic myelin peptides/proteins is 
highly efficient in inducing antigen-specific tolerance in vivo (15-22). In EAE this protocol not 
only prevented animals from disease, but even effectively reduced the onset and severity of all 
subsequent relapses when given after disease induction (17, 18, 23-25). As a major advantage of 
the therapy, tolerance can be simultaneously induced to multiple epitopes using a cocktail of 
myelin peptides (23).  
With the aim to induce antigen-specific tolerance in MS we adopted this promising tolerization 
strategy to treat patients with MS (supplementary Fig. S1). We have established a procedure for 
the manufacture of antigen-coupled cells using autologous peripheral blood mononuclear cells 
(PBMC) as carriers. Seven myelin peptides (MBP13-32, MBP83-99, MBP111-129, MBP146-
170, MOG1-20, MOG35-55, PLP139-154), which were previously identified as important 
targets of autoreactive T cells in MS (26-30) were coupled to the surface of PBMC by EDC. 
We assessed the feasibility, safety and tolerability of antigen-coupled cell tolerance in a first-in-
man, open-label, single center clinical trial in relapsing-remitting (RR) and secondary-
progressive (SP) MS patients (ETIMS-trial). Only patients, who had an antigen-specific T cell 
response against at least one of the peptides used in the trial, were eligible for treatment in the 
study and T cell reactivity was analyzed before and after treatment. 
 
Results 
Preparation and infusion of antigen-coupled cells 
At the day of study drug administration, 4-10x109 peripheral blood mononuclear cells (PBMC) 
and 200 ml autologous plasma were isolated from MS patients by leukapheresis (Cobe Spectra; 
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TerumoBCT, Belgium). The manufacturing process of peptide-coupled cells was started 
immediately, and all steps were performed under good medicinal practice (GMP) conditions in 
standard blood bags while maintaining a closed system (Fig. 1C). During this process PBMC 
were chemically coupled with 7 myelin peptides (MBP13-32, MBP83-99, MBP111-129, 
MBP146-170, MOG1-20, MOG35-55, PLP139-154). A detailed description of the 
manufacturing process can be found in the Methods. At the end of the manufacturing process, 
the autologous peptide-coupled cell product was re-suspended in 100 ml of autologous plasma 
for infusion (ETIMS cell product). Prior to infusion samples were analyzed to meet the following 
release criteria of the cellular product: residual EDC <1,9 µg/ml, endotoxin <0.5 EU/ml 
(Endosafe, Charles River, Wilmington, USA), viability (> 70% propidium iodide negative cells 
measured by flow cytometry), pH (7,2–7,8) and absence of aggregates (microaggregates <1/µl). 
The peptide-coupled cells were administered within 4 h after the last step of preparation of study 
drug product. The manufacturing process was feasible in all patients and all cell products 
fulfilled the release criteria. 
 
Adverse events including changes in vital signs, blood chemistry and blood cell counts after 
treatment with ETIMS cell product 
In order to determine safety and tolerability of treatment with ETIMS cell product, we evaluated 
the number and severity of AEs, significant changes in vital signs and changes in blood 
chemistry and blood cell counts. Twenty-four AEs, which were not considered MS-related, were 
reported at different times after treatment. The severity of these events as well as their putative 
relation with treatment are tabulated in Table 2. From these 24 AEs only 1 may be related to 
ETIMS product. Patient 2 reported a metallic flavor during infusion of study drug. The AE was 
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graded as mild, but relation to study drug could not be excluded. The same patient had an 
irritation of a punctured vein, which had been caused by the leukapheresis procedure but not the 
ETIMS product, since it was not administered through that vein. One serious adverse event 
(SAE) not related with ETIMS treatment, a diverticulitis of sigma, occurred in patient 1 six 
weeks after administration of study drug. 
No significant changes in vital signs were observed after ETIMS treatment. Hematological 
analyses did not reveal either clinically significant abnormalities following treatment in blood 
chemistry (data not shown) or blood cell counts (Fig. 2). The global number of eosinophils, 
basophils, neutrophils, lymphocytes, monocytes and platelets was stable after treatment in all 
patients including the four patients receiving higher dose of antigen-coupled cells (patient 6, 7, 8 
and 10). 
 
MS course after treatment with ETIMS cell product 
As an additional outcome measure for safety and tolerability we assessed if the ETIMS treatment 
led to worsening of MS. Worsening of MS was determined by neurological examination, i.e. 
occurrence of exacerbations and/or disability progression and, as the most sensitive measure, the 
occurrence of new T2 lesions or contrast-enhancing lesions (CELs) by magnetic resonance 
imaging (MRI). Since the main aim of this trial was to assess feasibility, safety and tolerability, 
the first six patients selected (patient 1-6) were patients with low disease activity in order to 
avoid that naturally occurring disease activity confounded the assessment of tolerability and 
safety. None of the first 6 patients treated with antigen-coupled cells (patients 1-6) showed a 
relapse during the first three months after treatment (Fig. 3). Concerning the three more active 
patients (patient 7, 8 and 10), patient 7 and patient 8 showed one MS disease exacerbation 
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following treatment at days 10 and 16 , respectively (Fig. 3). Both patients had high disease 
activity before inclusion in the study and the clinical presentation or MRI findings at the time of 
relapse were not uncommon with respect to prior disease history. Patient 7 presented with mild 
dysfunction in fine motor skills and dysaesthesia in both upper extremities. MRI revealed a CEL 
in the cervical spinal cord. Symptoms remitted completely following corticosteroid treatment. 
Patient 8 presented with dysaesthesia for temperature sensation in the right leg. MRI showed 
contrast enhancement in the cervical spinal cord lesion, which was already present the month 
before treatment. At this time the patient had a myelitis with residual paraesthesia in both legs. 
After corticosteroid treatment the symptom remitted. No further relapse occurred during the trial 
in these patients, and further clinical follow-up of the two patients with relapses disclosed 
reduced disease activity during the treatment period and follow-up compared to their disease 
activity prior to enrolment and during the baseline period. 
Neurologic function remained stable in all patients during the six months following treatment. 
There was no increase in neurological disability measured by Expanded disability status Scale 
(EDSS), Scripps Neurological Rating Scale (SNRS), Multiple Sclerosis Impact Scale (MSIS29) 
(Figure 5) nor Multiple Sclerosis Functional Composite (MSFC).  
All patients completed the MRI protocol. The number of new T2 lesions as well as CELs  before 
and at different time points after treatment for the first 6 patients with low disease activity are 
summarized in Fig. 4 (upper graphs). No increase in CEL or new T2 lesions was observed in 
these 6 patients. Regarding the second (dose-escalation) cohort, which was composed of more 
active patients (patient 7, 8 and 10), new CELs as well as new T2 lesions were detected after 
treatment (Fig. 4). In all three patients a single new T2 lesion was detected at week 2, and, even 
though these were small lesions that did not look different from previously observed T2 lesions 
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in each patient, it cannot not be completely excluded that these were related to the ETIMS 
treatment. Although the number of patients is very small, the number of new T2 and CEL is 
lower compared to baseline in patient 8, and slightly elevated in patient 7 and patient 10. 
After completion of the three months protocol, all patients were followed further as part of the 
safety analysis. During this period one MS exacerbation was observed in patient 3 and patient 5, 
respectively (Fig. 3). Patient 3 presented in week 18 with a hypaesthesia in the left leg without 
motor deficits. A corresponding CEL was seen on the spinal cord MRI. The hypaesthesia 
remitted completely following corticosteroid treatment. Patient 5 presented in week 17 with mild 
paresis of the right hand, a symptom, which she had experienced several times previously. While 
it remained unclear if these symptoms constituted a relapse, they were counted as such. Clinical 
examination and routine laboratory ruled out acute infection and brain MRI did not show any 
CEL or new T2 lesion. Symptoms completely resolved after corticosteroid treatment. Finally, we 
want to mention that patient 6 reported a transient increase in spasticity three months after study-
drug-administration, which is a common symptom in MS and induction by the treatment was 
unlikely at this late point. 
 
Characterization of blood cell populations after treatment with ETIMS cell product 
As a supplementary measure to determine safety and tolerability of ETIMS treatment, we also 
characterized by flow cytometry several relevant immune cell populations before and after 
treatment in whole blood obtained from the four patients receiving the higher dose of antigen-
coupled cells, patients 6, 7, 8 and 10.  Frequencies of monocytes, B cells, T cells, NK cells and 
NK-T cells before and after treatment are shown in Fig. 6A. ETIMS treatment did not induce 
significant changes in the percentage of any of these immune cell populations. Frequencies of 
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several functional CD4+ T cell subsets including Th1 (IFN-γ -producing cells), Th2 (IL-4-
producing cells), Th17 (IL-17-producing cells), Tr1 (IL-10-producing cells) and regulatory T 
cells (Treg, FoxP3-expressing cells) were also analyzed before and after treatment. Results are 
summarized in Fig. 6B, and individual data of patients in the high-dose group are shown in 
supplemental Fig. S3. With regard to safety of the regimen it is important to note that we did not 
detect increases in the frequency of Th1 or Th17 CD4+ T cell subsets 3 months after treatment. 
The frequency of Tr1, Treg and Th2 cells remained stable during the course of the study. 
Frequencies of several functional CD8+ T cell subsets including “regulatory” CD8+ T cells 
(CD8+ CD57+ ILT2+ T cells) and “pro-inflammatory” CD8+ T cells (CD8+ CD161high T cells) 
were stable following ETIMS treatment (Figure 6C; individual data of patients in the high-dose 
group are shown in supplemental Fig. S3).  
 
Characterization of myelin-specific T cell responses after treatment with ETIMS cell product 
To address whether antigen-coupled cells had an effect on the frequency of T cells specific for 
the antigens used in this study, we measured antigen-specific T cell responses before and three 
months after treatment. The percentage of positive wells, i.e. wells with scintillation counts 
(CPM) higher than the mean plus 3 standard deviations (mean+3xSTDEV) of the unstimulated 
wells, for each peptide before and after treatment in all patients receiving the lower dose of 
antigen-coupled cells (patients 1-5) and in the patients receiving the higher dose (patient 6, 7, 8 
and 10), is summarized in Fig. 7.  
Before treatment, patients were considered to have a positive T cell response against a specific 
peptide if they showed 2 or more positive wells, i.e. wells with CPM > Mean+3xSTDEV of 
unstimulated wells. The ETIMS treatment was considered to have an effect, when a reduction of 
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2 or more positive wells was observed three months after treatment. Patient 6 showed positive T 
cell responses before treatment (more than 2 wells with CPM > Mean+3xSTDEV of 
unstimulated wells) to all seven myelin peptides (MOG 1-20, MOG 35-55, MBP 13-32, MBP 
83-99, MBP 111-129, MBP 146-170 and PLP 139-154). Three months after treatment, T cell 
responses to all of these peptides (MOG 1-20, MOG 35-55, MBP 13-32, MBP 83-99, MBP 111-
129, MBP 146-170 and PLP 139-154) were reduced (Fig. 7). Patient 7 showed positive T cell 
responses against four different peptides (MOG 1-20, MOG 35-55, MBP 146-170 and PLP 139-
154) before treatment, and these responses were all reduced after treatment (Fig. 7). A positive 
response to MBP 13-32 was measured in patient 7 in a single well, and this was also reduced 
after treatment. Patient 8 showed positive responses before treatment against MOG 1-20, MOG 
35-55, MBP 13-32, MBP 83-99, MBP 111-129 and these responses were also reduced after 
treatment. In patient 8 a single well was positive against MBP 146-170, and this was reduced 
after treatment. Finally, patient 10 showed before treatment positive T cell responses to all seven 
myelin peptides (MOG 1-20, MOG 35-55, MBP 13-32, MBP 83-99, MBP 111-129, MBP 146-
170 and PLP 139-154), and the response to all of these peptides were reduced after ETIMS 
treatment (Fig. 7).  
 
Discussion 
In this first-in-man trial we have established the feasibility of antigen-coupled cell tolerization in 
MS and provide evidence for the safety and tolerability of this novel therapeutic approach. 
Tolerization by ETIMS involves autologous PBMC pulsed with seven myelin peptides in the 
presence of the coupling agent EDC. EDC catalyzes the formation of peptide bonds between free 
amino- and carboxyl groups, thereby producing peptide-coated cells that function as highly 
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tolerogenic carriers. This therapy is in many aspects novel and unique including the use of a set 
of peptides that covers the immunodominant epitopes of different myelin proteins. Six peptides 
of these three myelin proteins (MOG, MBP and PLP) were chosen because they were previously 
shown to be targets of the high-avidity autoimmune T cell response in MS (26). MBP 83-99 was 
added since it has been shown to be immunodominant in MS patients by many prior studies and 
has been a target of previous tolerization trials (3, 31, 32). To the best of our knowledge this is 
the first tolerization strategy that simultaneously targets 7 peptides from 3 myelin proteins. 
Previous tolerization approaches in MS patients mainly focused on single MBP peptides or MBP 
protein (31-33). Recently, transdermal application of 3 peptides from MBP, MOG and PLP 
showed efficacy in reducing myelin-specific T cell reactivity (34). Different from all other 
tolerization therapies antigen-coupled cell tolerance was shown to prevent epitope spreading in 
animal models. Further, tolerization with antigen-coupled cells has been shown to act in part 
independently of the MHC in mice, and may thus potentially be applicable for both human 
leukocyte antigen (HLA) DR15-positive and DR15-negative MS patients (35).  
To translate this regimen from mice to MS patients we have developed a manufacturing process 
for antigen-coupled cells, which is completely performed under GMP conditions in standard 
blood bags while maintaining a closed system (Fig. 1 and supplementary Fig. S1). The 
autologous cell product can be re-infused within the same day, which renders it a feasible 
approach for the outpatient care setting.  
For safety reasons it was requested by the regulatory authorities that we perform a very careful 
dose escalation starting with 1x103 cells in the first patient up to the target dose of 3x109 antigen-
coupled cells in the last patient. We did not encounter relevant safety concerns related to the 
study drug and have thus met the primary endpoint set for this first-in-man study. There was a 
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single SAE during the 3 months core study period, which was considered not related to the 
therapy by both the investigators and the independent DSMB, all other AEs were graded as mild 
or moderate. A critical issue in antigen-specific therapies is the risk of induction of disease by 
the treatment as previously observed in a vaccination trial using an altered peptide ligand (31). 
Therefore, we aimed to include patients, who did not have highly active disease in this first-in-
man trial. Since we did not observe induction of disease in the first six patients, we expanded our 
dose-escalation regimen with three more patients, who had clinically active disease. In two of 
these patients we observed exacerbations and new T2 MRI lesions 10 and 16 days after therapy 
(Fig. 3 and Fig. 4). Importantly, in both cases the presentation of the exacerbation was similar or 
identical to symptoms that the patients had experienced during recent months prior to treatment, 
and hence different from what had been observed in a trial using a altered peptide ligand (31). In 
the latter trial, 3 out of 8 patients experienced exacerbations with clinical- and/or MRI 
presentation that were very different from the patients’ prior history, and the massive increase of 
MBP peptide-specific T cells left little doubt that relapses had been treatment-induced (31). 
There was no increase in disability over the course of the study in any of the patients (Fig. 5). As 
stated above, we cannot exclude completely that the disease activity (exacerbations or new MRI 
lesions), which was observed within the first couple of weeks in the small group of highly active 
patients, was related to the ETIMS therapy, although we would have expected that it occurred 
even earlier in the trial, had this been the case. Of note, no further relapse occurred during the six 
months follow-up period in any of the highly active patients (patients 7, 8 and 10). However, the 
data raise the question if the dose of peptide-coupled cells should not be escalated even further. 
The two observed exacerbations in patients treated with a high-dose of antigen-coupled cells are 
an important safety signal. Therefore, strict safety measures, both clinical and MRI, are 
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warranted in future applications of antigen-coupled cells during clinical trials. 
Although the primary aim of the study was safety and tolerability, another important objective 
was to gather information on its immunologic effects. Thus, we treated only patients in whom a 
T cell responses towards the myelin peptides used in the trial could be measured at baseline. 
Interestingly, myelin peptide-specific T cell responses at baseline were higher in those patients 
with ongoing inflammatory disease activity. Patients treated in the high dose group (patients 6, -
7, 8 and 10) showed a uniform reduction in myelin-specific T cell response, although a few 
positive wells were measured in patients 6, 7 and 10 following treatment (Fig. 7). Therefore, 
together with the above clinical/MRI data we conclude with respect to dose-finding that 
minimally a dose of 3x109 peptide-pulsed cells or even more should be used, and given the good 
tolerability of the regimen, further dose escalation is not expected to pose problems. Three 
patients (1, 7 and 8) were HLA-DR15 positive, thus a definite conclusion on the influence of the 
HLA cannot be drawn. In a mouse EAE model, it has been shown that, while antigen-coupled 
cells can induce tolerance independently of the MHC, tolerance induction with peptide-coupled 
allogeneic cells required the administration of higher cell numbers than syngeneic cells or 
repeated injections (14, 35). Thus, beside a further dose escalation, as already mentioned, future 
trials should consider to give repeated injections of autologous antigen coupled cells.  
The exact mechanism of action of the tolerization regimen is not yet fully understood, but there 
is evidence that several distinct mechanisms are involved. It has been shown that antigen-
specific T cells encountering their cognate antigen/MHC complexes on EDC-treated cells are 
anergized as a result of failure to receive adequate CD28-mediated co-stimulation (36). However, 
in vivo, another mechanism might be more important, which is based on the fact that EDC 
efficiently induces apoptosis in treated cells. Experiments in animal models suggest that 
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apoptotic EDC-treated cells are phagocytosed in the spleen within a few hours by antigen 
presenting cells residing in this organ (immature dendritic cells or monocytes/macrophages), 
which leads to the production of IL-10 and expression of PD-L1 on macrophages as important 
factors for the induction of tolerance. Additionally, the induction of T regulatory cells plays a 
central role in the long-term maintenance of tolerance induced by this procedure (35, 37). In our 
patients we observed only a slight increase in the overall frequency of regulatory T cell subsets 
in peripheral blood, however, larger number of patients, who are treated with a homogeneous 
cell number, are needed to analyze this further. 
Contingent on future studies confirming the antigen-specific therapeutic effects of the regimen, 
antigen-coupled cell tolerance has the potential for wide applicability in different autoimmune 
diseases, transplantation tolerance and allergy. The feasibility and easy applicability, without the 
need for long term cell culture or expansion of cells ex vivo are major advantages of this 
approach. The clinical- and MRI data as well as the incomplete response with respect to reducing 
the frequency of myelin peptide-specific T cells in all of the small group of patients with highly 
active disease indicate that further dose escalation should be explored and that a better 
understanding of the mechanism/s of action in humans needs to be gained, and it is likely that 
this will be achieved in the phase IIa trial with a more homogeneous group of patients, who will 
all be treated with the same dose of cells. Despite these caveats, we believe that tolerization by 
ETIMS has distinct advantages over other approaches, which include the possibility for blocking 
epitope spreading and that only a single or few treatment courses are needed. Given the fact, that 
experimental studies demonstrated efficacy and safety of this approach in different T cell driven 
autoimmune diseases with defined antigens, allergy and transplantation, antigen-coupled cell 
tolerance could in principle be applied in several immunopathological conditions in humans, 
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however further data are clearly needed and it is open at this point if the effects of this treatment 
are equally broad in humans. 
 
Patients and Methods 
Ethics Statement 
The protocol was reviewed and approved by the Ethics Committee of the Hamburg Chamber of 
Physicians. An independent data and safety monitoring board (DSMB) oversaw the study. All 
procedures were done following the rules of the Declaration of Helsinki Guidelines and all 
regulatory steps were performed under guidance of the German regulatory authority for 
biologics/cell therapies, the Paul-Ehrlich Institute, Langen, Germany. The trial is registered 
under the EudraCT number 2008-004408-29. All patients signed a written informed consent 
before inclusion in the study. 
 
Preparation of antigen coupled cells 
Peripheral blood mononuclear cells (PBMC; 4-10x109) and 200 ml autologous plasma were 
isolated from MS patients by leukapheresis (Cobe Spectra; TerumoBCT, Belgium). Immediately 
after collection of cells, the manufacturing process was under GMP conditions in the clean room 
at the Institute of Transfusion Medicine, Center for Diagnostics, University Medical Center 
Hamburg-Eppendorf, Germany. Briefly, red blood cells were lysed by 15 min incubation in 200 
ml ACK lysis buffer (consisting of ammonium-chloride, PhEur [Merck, Darmstadt, Germany], 
potassium hydrogen carbonate, PhEur [Merck] and water for injection PhEur [Baxter, Germany]) 
at room temperature. Subsequently, PBMC were washed twice in 200 ml of saline (Baxter) 
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containing citrate-phosphate-dextrose buffer (CPD, Fresenius, Bad Homburg, Germany). After 
cell counting, 1.5-4x109 PBMC were re-suspended in 10-20 ml of saline and 1 ml containing 0.5 
mg of each GMP peptide was added (MBP13-32, MBP83-99, MBP111-129, MBP146-170, 
MOG1-20, MOG35-55, PLP139-154; Bachem AG, Bubendorf, Switzerland, the final 
concentration of each peptide in the coupling reaction was 0.05 mg/ml). The coupling reaction 
was initiated by the addition of 100-200 mg freshly prepared water-soluble EDC (AppliChem, 
Darmstadt, Germany). Following 1h shaking incubation at 4°C, the cells were washed 2 times 
with 100 ml CPD-saline and re-suspended in 100 ml of autologous plasma for injection.  
Coupling of the peptides on the surface of PBMC was verified during validation of 
manufacturing process and at regular intervals during the trial. Briefly, PLP139-154 was 
replaced by a biotinylated PLP139-154 peptide. At the end of the manufacturing process 
coupling of biotinPLP139-154 was visualized by FACS analysis using streptavidin conjugated 
with APC. The respective drug product was not used for patient injection, because the use of 
biotin-conjugated peptides is not licensed for use in humans. The binding efficiency was not 
tested individually for all peptides used in the trial, however from pre-clinical experience as well 
as the chemical properties of the peptides, it is expected that the coupling is efficient for all 
peptides. 
 
Trial Design and outcome measures 
Ten patients with RRMS (n=8) or SPMS (n=2) were included in this single-centre, open-label, 
phase I trial. Patient 9 withdrew from the study at month -2 prior to the treatment for personal 
reasons. The clinical and demographic data of patients treated with ETIMS cell product is shown 
in Table 1. Inclusion criteria included the following: ages between 18 and 55 years, RR-MS or 
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SP-MS disease course, disability score (expanded disability status scale, EDSS) between 1 and 
5.5 (38), patients had to be able to provide written informed consent prior to any testing under 
the protocol and patients had to have a specific T cell response against at least one of the 
peptides used in the trial (see antigen-specific T cell responses section in patients and methods). 
All patients included in the trial fulfilled this criterion by showing a T cell response against at 
least on of the peptides used in the trial. Exclusion criteria included the following: primary 
progressive MS, pregnancy and breast-feeding, history or actual signs of immunodeficiency, 
concurrent clinically significant cardiac, immunological, pulmonary, neurological, renal or other 
major disease, splenectomy and cognitive impairment. 
The primary outcome of the study was safety and tolerability and was determined by the (i) 
number and severity of adverse events (AEs), including (ii) significant changes in vital signs, 
(iii) changes in blood chemistry and differential blood counts and (iv) aggravation of the disease 
at month +3.  
The first cohort of six patients was followed for one month before study-drug-administration 
with two consecutive clinical magnetic resonance imaging (MRI) and general physical 
examinations as well as clinical and laboratory assessments (Fig. 1A).  A careful dose escalation 
was performed in these patients to ensure safety and reduce the risk for individuals (for details 
on the rationale for the lowest and highest dose see supplementary methods). Each patient 
received a single infusion of antigen-coupled cells. The first patient received 1x103, the second 
patient 1x105, the third patient 1x107, the fourth patient 1x108, the fifth patient 5x108 and the 
sixth 1x109 antigen-coupled cells. The last three patients (patient 7, 8 and 10) were included in 
the trial as an amendment to increase dose-escalation, and since safety was already documented 
more active disease patients were included. Patient 7 received 1x109 antigen-coupled cells, 
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patient 8 2.5x109 and patient 9 3x109. In these three patients the observation period before study-
drug-administration was extended to 3 months (Fig. 1A). At the day of study-drug-
administration, all patients were monitored in a phase I inpatient unit for 24 h (Fig. 1B). The trial 
design stipulated measurement of the primary outcome at month 3 and additional safety follow-
up until month 6 with consecutive clinical, MRI and general physical examinations as well as 
clinical and laboratory analyses to assess AEs and monitor MS disease activity (Fig. 1A). 
Hematological analyses including differential blood counts and clinical chemistry were 
performed in the Institute of Clinical Chemistry, University Medical Center Hamburg-Eppendorf. 
MS disease course was evaluated by neurological examination and MRI assessing presence of 
new T2 lesions or new contrast enhancing (CEL) on MRI, occurrence of exacerbations and 
disability progression. Neurologic function was scored with EDSS (38), the Scripps Neurologic 
Rating Scale (SNRS) (39) and the Multiple Sclerosis Functional Composite (MSFC)(40). The 
Multiple Sclerosis Impact Scale (MSIS29) was used as a patient based outcome measures of 
disability (41). 
 
Magnetic resonance imaging 
The MRI examinations were performed on a 1.5 Tesla MRI scanner MAGNETOM Sonata 
(Siemens, Germany) with a standard head coil at the Department of Neuroradiology, University 
Medical Center Hamburg-Eppendorf. The following sequences were obtained: T1 pre- and post 
gadolinium (0.1mM/kg, Gd-BOPTA); PD/T2-weighted images; FLAIR (fluid attenuated 
inversion recovery), and diffusion-weighted imaging sequences. All brain MRIs were analyzed 
by experienced neuroradiologists blinded for the clinical findings.  
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Flow Cytometric analysis 
Peripheral blood, before and after treatment with ETIMS cell product, was collected in EDTA-
tubes. Frequency of different cell subsets was analyzed in whole blood by flow cytometry using 
different antibody panels. Immune cell subsets (granulocytes, eosinophils, monocytes, B, T, NK 
and NKT cells) were assessed with anti-CD45 (PE-Cy7, eBioscience, San Diego, CA), anti-
CD16 (APC-Cy7, BioLegend, San Diego, CA), anti-CD19 (FITC, BD, Franklin Lakes, NJ), anti-
CD14 (V450, BD), anti-CD3 (PerCP, BD) and anti-CD56 (PE, eBioscience). Gating strategy is 
shown in supplemental Fig.S2. T cell subsets including CD4+, CD8+, CD4+ Treg (CD4+ FoxP3+), 
„regulatory“ CD8+ (CD8+ CD57+ ILT2+) and „proinflammatory“ CD8+ (CD8+ CD161high) T cells 
were analyzed using anti-CD3 (PE-Cy7, eBioscience), anti-CD4 (APC, eBioscience), anti-CD8 
(PB, Dako- BIOZOL, Eching, Germany), anti-FoxP3 (PE, Miltenyi), anti-CD25 (APC, 
eBiosciences), anti-CD57 (FITC, BD), anti-ILT2 (PE, Beckman) and anti-CD161 (APC, 
Milteny) antibodies. The corresponding isotype controls were included in all stainings. Cells 
were analyzed using a LSR-II flow cytometer (Becton Dickinson, BD) and FACS Diva Software 
(BD). 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient 
centrifugation (PAA, Pasching, Austria) and functional phenotype of T cells was evaluated by 
intracellular cytokine staining as follows, 5x105 freshly isolated PBMC were incubated over 
night in 200 µl x-Vivo15 (Lonza) in a sterile FACS tube. Next day cells were stimulated with 
PMA (50 ng/ml, Sigma, St Louis, USA) and ionomycin (1 µg/ml, Sigma) in the presence of 
brefeldin A (10 µg/ml, eBioscience) for 5 h. After washing with PBS cells were stained with 
LiveDead kit (AmCyan, Invitrogen), fixed, permeabilized and stained with different antibodies: 
anti-IL-17 (Alexa 647; ebiosciences), -IL-4 (PE-Cy7, Biolegend), -IFN-γ (FITC, Biolegend), -
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IL-10 (PE; Biolegend), -CD3 (PE, DakoCytomation), -CD4 (PB, DakoCytomation) and -CD8 
(PB, Biolegend) or with the corresponding isotype controls. 
 
Antigen-specific T cell responses 
The antigen-specific T cell responses towards the myelin peptides used in the study were 
measured in freshly isolated PBMC prior to the tolerization procedure and after 3 months. 
Antigen-specific T cell responses were analyzed by proliferation assays using thymidine 
incorporation. Briefly, isolated PBMC were seeded in 96 wells plates at 1,5x105 PBMC/well in 
x-Vivo-15 (Lonza, Basel, Switzerland) medium with 1µM of each peptide. 48 wells were seeded 
per antigen and 6 wells only with medium as negative control in each plate. Tetanus toxoid (TTx, 
5 µg/ml) (Novartis Behring, Marburg, Germany) was used as positive control. On day 7, plates 
were incubated for 15 h with 1 µCi of 3H-thymidine (Hartmann Analytic, Braunschweig, 
Germany). 3H-Thymidine pulsed plates were analyzed with a scintillation beta counter (Wallac 
1450, PerkinElmer, Rodgau-Jürgesheim, Germany). The scinitillation counts (CPM) of each well 
were measured. Wells showing CPM higher than the mean plus 3 standard deviations 
(mean+3xSTDEV) of the unstimulated wells were considered as positive.  
 
Statistical analysis 
Statistical analysis was done using GraphPad Prism 4 (GraphPad Software Inc.) software. 
Descriptive statistics are reported as mean ± SEM. The comparisons of clinical and 
immunological parameters were performed for two-group comparisons using a paired t-test. 
Comparisons of three groups and more were assessed by one-way ANOVA with Bonferroni’s 
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correction for multiple comparisons or Kruskal-Wallis test with Dunn´s post test depending on 
the distribution of the data. P-values <0.05 were considered statistically significant. 
 
Supplementary materials 
Fig S1: Schematic representation of the manufacture process. 
Fig S2: Gating strategy for blood cell subsets. 
Fig S3: CD4 and CD8 subsets in high-dose patients before and after treatment. 
Supplementary Methods: Rationale for choosing the lowest and highest dose. 
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Figures: 
Fig. 1. Study Design.  A) The first 6 patients were followed before treatment with two clinical-, 
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MRI- and laboratory examinations at month -1 before treatment and day 0 and after treatment at 
weeks 2, 6 and 3 months. Vital signs and AEs were recorded during infusion, 30 min, 1, 2, 4 h 
after infusion, on day +1, day +3, week +2, week +3, week +6 and month +3. General physical 
examination was performed at month -1 and day +1. Neurological examination was done at 
month -1, day -1, week +2, week +6, and month +3. Brain MRI was assessed at month -1, day -1, 
week +2, week +6 and month +3. MSIS29 was assessed at month -1, day +1, week +6 and month 
+3. Patients were further followed for AEs, serious AEs (SAE), clinical and MRI disease activity 
at months +4, +5 and +6. The last three patients were followed at four time-points (month -3 to 
D0) before treatment and further examinations were performed at week 2, months 1, 2, 3 and 6 
(scattered line). B) Patients were admitted to the Phase I unit the day prior to treatment. At D0 
leukapheresis was performed and the autologous cell product manufactured under GMP 
conditions. Following quality control study drug was infused the same day and patients 
monitored for AEs for 24 hours. C) Panel depicts the most important steps of the manufacturing 
process, which was performed in blood bags while maintaining a closed system. Erythrocytes are 
lysed with lysis buffer. The peptides are added and the coupling procedure is initiated by 
addition of EDC. Finally quality control is performed. As soon as all release criteria are fulfilled, 
the ETIMS cell product is used for therapy. * includes washing steps and cell counting. QC: 
quality control. 
 
Fig. 2. Peripheral blood cell counts after ETIMS treatment. Absolute peripheral blood counts 
(mean ± SEM) of eosinophils, basophils, neutrophils, lymphocytes, monocytes and platelets 
before treatment (month -1 and day -1) and after treatment (day 1, week 2, week 6 and month 3). 
Dotted line indicates the time point of study-drug-administration. 
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Fig. 3. Clinical exacerbations after ETIMS treatment. Clinical exacerbations in the year 
before treatment (grey circles), during the first three months after treatment (black circles) and 
during the safety follow-up until month 6 for the nine patients included in the trial. Dose of 
antigen-coupled cells is shown on the right side. Dotted line indicates the time point of study 
drug administration.  
 
Fig. 4. New T2 lesions and CEL after ETIMS treatment. New T2 lesions (left graphs) and 
CEL (right graphs) in the first cohort of patients with low disease activity (patients 1-6) (upper 
graphs), and in the last three patients with higher disease activity (patient 7, 8 and 10) (lower 
graphs). Mean ± SEM is shown in the two upper graphs corresponding to patients 1-6. T2 lesions 
graphs: y-axis is number of T2 lesions, first column in grey indicates the number of total T2 
lesions three months before study-drug-administration, columns in black indicate new T2 lesions 
before treatment (months -2, -1 and 0) and after treatment (week 2, months 2, 3, 4, 5 and 6). CEL 
graphs: y-axis is number of new CEL lesions (both brain and spinal cord CEL), new CEL before 
treatment (month -3, -2, -1 and 0) and after treatment (week 2, month 2, 3, 4, 5, and 6) are shown. 
Dotted line indicates the time point of study drug administration. 
 
Fig. 5. Neurologic function after ETIMS treatment. EDSS (left graphs), SNRS (middle 
graphs) and MSIS29 (right graphs) in the first cohort of patients with low disease activity 
(patients 1-6) (upper graphs), and in the last three patients with higher disease activity (patient 7, 
8 and 10) (lower graphs) before treatment (months -3 and -1) and after treatment (week 2, 
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months 3 and 6). Mean ± SEM is shown in the three upper graphs corresponding to patients 1-6. 
Dotted line indicates the time point of study drug administration. 
 
Fig. 6. Immune cell subsets after ETIMS treatment. Percentage of B (CD45+ CD19+), 
monocytes (CD45+ CD14+), T (CD45+ CD3+ CD56-), NK (CD45+ CD3- CD56+) NKT (CD45+ 
CD3+ CD56+) cells (A.), CD4+ T cells (CD3+ CD4+ CD8-) (B) and CD8+ T cells (CD3+ CD4- 
CD8+) (C) measured by flow cytometry in the four patients receiving the higher dose of antigen 
couple cells (patients 6, 7, 8 and 10) before (month -1 and day -1) and after (week 2 and month 
3) ETIMS treatment. Percentage of Th1 (CD4+ IFN-γ+), Th17 (CD4+ IL-17+), Th2 (CD4+ IL-4+), 
Treg (CD4+ FoxP3+) and Tr1 (CD4+ IL-10+) (B) and “regulatory” CD8+ (CD8+ CD57+ ILT2+) 
and “proinflammatory” CD8+ (CD8+ CD161high) (C) T cells measured by flow cytometry in the 
four patients receiving the higher dose of antigen-coupled cells (patients 6, 7, 8 and 10) before 
(month -1) and after (month 3) ETIMS treatment. Mean ± SEM is shown. Dotted line indicates 
the time point of study drug administration. 
 
Fig. 7. Myelin specific T cell response after ETIMS treatment. A) MOG 1-20, MOG35-55, 
MBP 13-32, MBP 83-99, MBP 111-129, MBP 146-170, PLP 139-154, TTx -specific T cell 
responses and unstimulated wells before (month -1) and after (month 3) ETIMS treatment in 
patients treated with low (1x103 – 5x108, patients 1-5; left panel) or high (1x109 – 3x109, patients 
6, 7, 8 and 10; right panel) dose of antigen-coupled cells. Proliferative responses were measured 
by 3H-thymidine incorporation assay. Graphs (y-axis) represent the scintillation counts per 
minute (CPM). The dotted line represents the threshold set for the mean + 3x standard of 
unstimulated wells. All wells above this threshold are shown in red.  
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Supplementary Materials: 
Fig. S1. Schematic representation of the manufacture process. Autologous PBMC are 
collected by leukapheresis and subsequently pulsed with 7 myelin peptides in the presence of 
EDC. The whole procedure including the washing steps is performed in standard blood bags. 
After quality control the autologous cell product is infused the same day.  
 
Fig. S2. Gating strategy for blood cell subsets. CD45+ cells (leukocytes), CD16high 
(granulocytes), CD45+ CD16- (leukocytes without granulocytes), CD45+ CD16- CD19+ (B cells), 
CD45+ CD16- CD14+ (monocytes), CD45+ CD16- CD14- CD19- CD3+ CD56- (T cells), CD45+ 
CD16- CD14- CD19- CD3+ CD56+ (NKT cells) and CD45+ CD16- CD14- CD19- CD3- CD56+ 
(NK cells).  
 
Fig. S3. CD4+ and CD8+ T cell subsets after ETIMS treatment 
Percentage of CD4+ T cell subsets (left panel) Th1 (CD4+ IFN-γ+), Th17 (CD4+ IL-17+), Th2 
(CD4+ IL-4+), Treg (CD4+ FoxP3+) and Tr1 (CD4+ IL-10+) and CD8+ T cell subsets (right panel) 
“regulatory” CD8+ (CD8+ CD57+ ILT2+) and “proinflammatory” CD8+ (CD8+ CD161high) T cells 
measured by flow cytometry in the four patients receiving the higher dose of antigen-coupled 
cells (patients 6, 7, 8 and 10) before (month -1) and after (month 3) ETIMS treatment. Mean ± 
SEM is shown.  
 
Supplementary Methods: Rationale for choosing the lowest and highest dose. 
At the beginning of the developmental process we aimed for a maximum dose of 1x109 antigen 
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coupled cells. This target cell number was based on calculations derived from both in-vivo and 
in-vitro data taking into account both efficacy and safety following the considerations outlined 
below:  
1) In pre-clinical studies in mice, the efficacy of the treatment with antigen-coupled cells has 
been assessed by comparing antigen-specific recall responses by DTH between syngeneic SJL 
mice compared to sham-treated mice. Different doses of antigen-coupled cells have been tested 
ranging from 5 x 106 to 1 x 108 cells. In SJL mice 1 x 107 injected donor cells were the lowest 
amount of cells with a significant difference in ear swelling compared to controls. Thus we 
deduced this dose as minimum effective dose in mice. If this minimally effective dose is taken to 
estimate the minimal anticipated biological effect level (MABEL), the following dose represents 
the MABEL: 1 x 107/20g = 30 x 109/60kg, and after adjustment for the human equivalent dose 
(HED), i.e. division by 12.3, the final MABEL dose in humans is 2.44 x 109 cells/60 kg. 
2) The level with no observable adverse effect (NOAEL) was calculated according to the 
Guidance for Industry and Reviewers, Estimating the Safe Starting Dose in Clinical Trials for 
Therapeutics in Adult Healthy Volunteers. In mice we have not observed any adverse effects 
injecting 5 x 107 cells (5 x 107 /20g = 2,5 x 109 cells/kg), which is the human equivalent dose 
(HED) based on conversion mg/kg (divide mouse dose by 12.3) of 12  x 109 cells per 60 kg 
person. 
3) The in-vitro potency determinations showed a reduction of antigen-induced proliferation, i.e. a 
pharmacodynamic effect, to approximately 55% at a ratio of 1:8 between antigen-specific T cell 
clone and EDC-fixed, peptide-pulsed PBMCs (tPBMCs). If we were to base our MABEL 
estimates on these in-vitro data in humans, we considered the following: Our and other groups’ 
extensive studies on the precursor frequencies of myelin antigen-specific autoreactive T cells in 
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the peripheral blood of humans have shown the following precursor frequencies: If frequency 
estimates are based on data generated with ELISPOT (interferon-gamma secreting cells upon 
stimulation with myelin peptide (Olsson et al., 1990 and 1992) frequencies ranged between 
1/10,000 PBMC to 1/100,000 PBMC. Most studies including ours used limiting dilution-based 
in-vitro culture systems and generated the following frequencies for T cells specific for an 
individual myelin peptide or protein: 1/100,000 PBMC (as the highest) to between 1/1.000,000 
and 1/10.000,000 PBMC (the latter is the range that was most frequently observed, (Martin et al., 
1993, Bielekova et al., 2000). 
Hence the estimated minimally required number of tPBMCs to tolerize an individual antigen-
specific T cell clone in-vivo is 125 cells. Since the tPBMCs to be used under ETIMS are pulsed 
with 7 peptides, this number probably needs to be multiplied by 7, i.e. 875 tPBMCs. This 
number is 11.4 x 104 lower than the minimally effective in-vivo dose of antigen-coupled cells in 
mice (i.e. 1 x 107 antigen-coupled cells; see above).  
4) If we consider both this minimally effective in-vivo dose of antigen-coupled cells in mice (i.e. 
1 x 107; see above) and the above calculated putative minimally effective in-vivo dose of 
tPBMCs in humans to tolerize individual autoreactive TCCs (875 tPBMCs), we arrive at the 
following range for MABEL:  
 
mouse-derived number for MABEL: 2.44 x 109 tPBMCs/60 kg 
human-derived number for MABEL*: 875 tPBMCs/60 kg 
 
In summary of the above, we considered the following for the first-in-man trial. In the phase I 
and dose finding, the maximum recommended starting dose would be the one derived from the 
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mouse-derived number for MABEL (2.44 x 109 tPBMCs/60 kg), however at that time we were 
afraid that it will be difficult to reach 2x109 tPBMCs for the trial (and therefore our treatment 
dose has been set at 1x109 tPBMCs). 
The maximum recommended starting dose from the human-derived number for MABEL is 875 
tPBMCs/60 kg. Therefore, we have stipulated the following starting dose and tPBMCs numbers 
for the dose finding: 
 
First patient:   0.875 - 1 x 103 tPBMCs (which is the MABEL derived from the human 
numbers assuming the lowest number of autoreactive precursor cells from 
the literature, i.e. 1 x 10-7 cells, see above)  
Second patient: 1 x 105 tPBMCs  
Third patient: 1 x 107 tPBMCs 
Fourth patient: 1 x 108 tPBMCs 
Fifth patient: 5 x 108 tPBMCs 
Sixth patient:  1 x 109 tPBMCs 
 
After the experience with the first six patients and the favorable safety and tolerability data we 
chose to expand the dose escalation to reach the mouse-derived MABEL ie. 2.44 x 109 tPBMCs. 
Despite our careful attempts to estimate MABEL and NOAEL from mouse data to humans, it is 
clear that there remain uncertainties, because validated prior evidence for such equivalence 
calculations do not exist for cell-based therapies and particularly do not take into account the 
substantial differences between the immune systems in rodents and 
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